Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology

SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and SOPHiA GENETICS (NASDAQ: SOPH) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients.

GlobeNewsWire • 15 hours ago

SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology

BOSTON, Oct. 8, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients.

PRNewsWire • 15 hours ago

Jefferies maintains 'buy' rating on AstraZeneca ahead of third-quarter results

Jefferies maintained a 'buy' rating on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the biopharmaceutical company, with a 17,500p price target, representing 46% potential upside from its 11,958p share price. The broker expects AstraZeneca to report third-quarter revenue about 1% ahead of the Visible Alpha consensus and core earnings before interest and tax at 3% above expectations.

Proactive Investors • Oct 7, 2026

Citi raises AstraZeneca target to £186 as tozorakimab prospects improve

Citi raised its target price for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceutical company, to £186 from £178 and retained its 'buy' rating after recent clinical developments. The broker increased its peak sales forecast for tozorakimab to $7 billion and for SERENA-6 to $1.1 billion, more than offsetting the removal of its $1.7 billion forecast for SERENA-4.

Proactive Investors • Oct 6, 2026

Astrazeneca (AZN) Exceeds Market Returns: Some Facts to Consider

In the latest trading session, Astrazeneca (AZN) closed at $158.61, marking a +1.33% move from the previous day.

Zacks Investment Research • Oct 6, 2026

AstraZeneca to invest over $1 billion in Massachusetts, boost workforce

AstraZeneca said on Monday it would spend more than $1 billion in Massachusetts ​as part of its broader $50 billion US ‌investment plan, a move expected to expand its workforce in the state by more than 50% in ​the coming years.

Reuters • Oct 5, 2026

AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment

AstraZeneca CEO Pascal Soriot told CNBC that Summit Therapeutics' lead drug could help power next-generation cancer combinations that could be the "future of cancer care." Soriot spoke exclusively with CNBC from the site of AstraZeneca's new more than $1 billion research and development facility in Kendall Square in Cambridge, Massachusetts.

CNBC • Oct 5, 2026

AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the opening of its newest global strategic research and development (R&D) center, in Kendall Square, Cambridge, Massachusetts. The new state-of-the-art facility builds on the Company's existing presence in Cambridge and Boston and places its scientists at the heart of one of the world's most innovative life sciences ecosystems. Together with its site for genomic medicine at 100 Binney Street, The AstraZeneca R&D Center Kenda.

Business Wire • Oct 5, 2026

SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos

Summit is teaming up with AstraZeneca and Daiichi to test ivonescimab with Datroway across breast and lung cancers, broadening its potential.

Zacks Investment Research • Oct 5, 2026

AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the successful closing of AstraZeneca's (LSE/STO/NYSE: AZN) strategic equity investment in Summit. The equity investment will support continued acceleration of the development of ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody. Pursuant to the terms of the Securities Purchase Agreement entered into by Summit and AstraZeneca, AstraZeneca purchased an aggregate of approxi.

Business Wire • Oct 5, 2026